Sonova Holding AG stock (CH0012549785): shares steady after recent full-year 2024/ 25 results

Sonova Holding AG shares on SIX Swiss Exchange traded broadly steady on Friday after the Swiss hearing-care group published its full-year 2024/25 results earlier in the week, giving investors fresh insight into margins, cash flow and valuation metrics.

Sonova Holding AG shares on SIX Swiss Exchange traded broadly in line with the Swiss market on Friday, as investors continued to assess the Swiss hearing-care company’s recently reported full-year 2024/25 results and updated outlook for the current financial year.

The stock traded in Swiss francs on SIX under the ticker SOON, leaving the company firmly anchored in its home market of Switzerland, where it is part of the SPI index and closely watched by domestic investors. The latest full-year figures, released in late May 2025 according to the company’s investor relations communications, highlighted developments in revenue, profitability and cash generation that now feed directly into valuation multiples such as the price-earnings ratio and enterprise-value-based metrics used by analysts.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Sonova
• Sector/industry: Hearing-care medical technology and audiology solutions
• Headquarters/country: Stäfa, Switzerland
• Core markets: Europe, North America and Asia-Pacific
• Key revenue drivers: Hearing instruments, cochlear implants and audiological services networks
• Home exchange/listing venue: SIX Swiss Exchange (SOON)
• Trading currency: CHF

Sonova Holding AG: core business model

Sonova generates most of its revenue by designing and supplying hearing instruments, cochlear implant systems and related audiological services, with sales driven by its global retail network and partnerships with hearing-care professionals.

Valuation metrics and multiples for Sonova Holding AG

With Friday’s trading taking place on SIX Swiss Exchange in Swiss francs, Sonova’s valuation is typically assessed using earnings and cash-flow-based metrics that reflect its profile as a profitable, dividend-paying medical technology group focused on hearing-care solutions. For investors following the Swiss market, the company’s most recent full-year 2024/25 financial statements, published in May 2025 on its investor relations pages, provide the key inputs for commonly used ratios such as the price-earnings (P/E) multiple, enterprise value to EBITDA (EV/EBITDA) and dividend yield on the basis of the last distribution proposal approved at the annual general meeting.

On a P/E basis, market participants usually compare Sonova’s share price in CHF with its earnings per share from the most recently completed financial year, allowing a like-for-like comparison with other Swiss-listed healthcare and medtech companies. In parallel, the EV/EBITDA ratio incorporates the company’s market capitalization, net debt and lease liabilities relative to operating earnings before depreciation and amortization, a metric that is closely watched because the group has been investing in its retail footprint and technology pipeline while maintaining a focus on cash generation. Dividend yield, derived from the latest CHF per-share dividend approved for the prior fiscal year, remains another core valuation reference point, particularly for income-oriented investors in Switzerland who track the stability of distributions and the payout ratio.

Beyond these headline multiples, some analysts also consider free cash flow yield and price-to-sales ratios when assessing Sonova’s positioning versus other listed hearing-care and medical technology peers. These metrics are influenced by the company’s ability to translate revenue growth into operating cash flow and by the scale advantages from its global retail network and manufacturing base. As the market digests the full-year 2024/25 numbers released in May 2025 and incorporates any guidance the company has provided for the 2025/26 financial year, Sonova’s valuation on SIX continues to reflect both its defensive healthcare profile and its exposure to structural demand for hearing solutions.

Conclusion

Sonova’s share price performance on SIX Swiss Exchange at the end of the week reflects a market that is digesting the company’s full-year 2024/25 results, with valuation ratios now grounded in the latest reported earnings and cash flow figures. Against this backdrop, metrics such as P/E, EV/EBITDA and dividend yield help investors position the stock within the broader Swiss healthcare and medical technology universe without implying a particular direction for the shares. How these valuation measures evolve will depend on Sonova’s execution on growth initiatives, margin management and capital allocation in the current financial year.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.